Astellas' Phase III Front-Line AML Study Of Xospata Fails
Standard Of Care Has Shifted Since Trial's Initiation
One expert said the company should focus efforts on developing the drug for maintenance treatment of AML.
You may also be interested in...
Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The latest drug development news and highlights from our US FDA Performance Tracker.
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.